Matthew Arismendez, PA
Physician Assistant · San Antonio, TXNPI 1346646510
Payments from drug & device makers
Across 320 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$976
- Novo Nordisk$550
- Bayer$539
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$449
- AstraZeneca$397
- Sumitomo Pharma America, Inc.$280
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,97595%
- Education$2415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $976 |
| Novo Nordisk | 31 | $550 |
| Bayer | 42 | $539 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $449 |
| AstraZeneca | 17 | $397 |
| Sumitomo Pharma America, Inc. | 14 | $280 |
| Astellas Pharma US Inc | 8 | $255 |
| Boehringer Ingelheim | 12 | $217 |
| GSK | 11 | $199 |
| Lilly USA, LLC | 9 | $171 |
| Merck | 10 | $152 |
| Johnson & Johnson | 5 | $110 |
| Avanir Pharmaceuticals, Inc. | 4 | $88 |
| Axsome Therapeutics, Inc. | 5 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Pfizer | 4 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $62 |
| Abbott | 3 | $61 |
| Shield Therapeutics Inc | 3 | $61 |
| Corium, LLC | 3 | $45 |
| Ardelyx, Inc. | 2 | $44 |
| Exact Sciences | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Seqirus USA Inc | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Si-bone, Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Alk-abello, Inc | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Amgen | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
| Novartis | 1 | $12 |
How this compares
$5,216 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $174,591 |
| MounjaroTirzepatide | 58 | $64,365 |
| VraylarCariprazine Hcl | 38 | $56,803 |
| TrulicityDulaglutide | 51 | $56,375 |
| JardianceEmpagliflozin | 37 | $47,887 |
| LinzessLinaclotide | 39 | $45,118 |
| JanuviaSitagliptin Phosphate | 32 | $40,244 |
| FarxigaDapagliflozin Propanediol | 32 | $39,452 |
| EliquisApixaban | 28 | $37,340 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $36,083 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $25,468 |
| RybelsusSemaglutide | 17 | $23,628 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,696 |
| TradjentaLinagliptin | 12 | $16,082 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $14,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $550 | $198,219179 claims |
| Lilly USA, LLCMounjaro, Trulicity | $171 | $120,740109 claims |
| AbbVieVraylar, Linzess | $976 | $101,92177 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $397 | $79,17095 claims |
| Boehringer IngelheimJardiance, Tradjenta | $217 | $63,96949 claims |
| MerckJanuvia | $152 | $40,24432 claims |
| PfizerEliquis | $67 | $37,34028 claims |
| GSKTrelegy Ellipta | $199 | $25,46824 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $280 | $8,12312 claims |
| Astellas Pharma US IncMyrbetriq | $255 | $7,75911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in San Antonio
- Anthony DerenciusSan Antonio$507K
- Andrew PrattSan Antonio$87K
- Sarah MerrittSan Antonio$55K
- Monica ChapmanSan Antonio$38K
- Lisa GarrisonSan Antonio$35K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.